ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Strategic IDN Account Representative at Crinetics Pharmaceuticals - ApplyBlast

Strategic IDN Account Representative

Crinetics Pharmaceuticals

4 months ago

3.2 on Glassdoor

Texas

Hybrid

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Strategic IDN Account Representative serves as the single-threaded enterprise owner for Kaiser Permanente, leading strategy and execution for one of Crinetics' most critical integrated delivery networks. The role ensures formulary access translates into real-world patient adoption by partnering cross-functionally on pathways, protocols, and EMR integration while managing executive-level stakeholders.

Responsibilities

Lead enterprise-wide strategy and execution across Kaiser Permanente regions
Own formulary access and P&T committee engagement workflows
Drive pathway and EMR integration following access decisions
Build trusted relationships with executive-level stakeholder teams
Partner with Market Access on contracting and financial analysis

Skills

Qualifications

Bachelor's degree in Business or Science

About Crinetics Pharmaceuticals

crinetics.com

Headquarters

San Diego, California, United States

Company Size

201-500 employees

Founded

2008

View Profile

Crinetics Pharmaceuticals, now a Vertex Pharmaceuticals company, is a pharmaceutical company dedicated to discovering, developing, and commercializing treatments for endocrine diseases. Based in San Diego, CA, the company maintains a pipeline of novel therapies including Paltusotine (an oral SST2 agonist) and Atumelnant (an oral ACTH antagonist). Crinetics aims to be the premier endocrine-rooted global pharmaceutical company, focused on improving the lives of patients with endocrine disorders.